ES2537104T3 - Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelular y métodos de identificación de las mismas - Google Patents
Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelular y métodos de identificación de las mismas Download PDFInfo
- Publication number
- ES2537104T3 ES2537104T3 ES10009857.3T ES10009857T ES2537104T3 ES 2537104 T3 ES2537104 T3 ES 2537104T3 ES 10009857 T ES10009857 T ES 10009857T ES 2537104 T3 ES2537104 T3 ES 2537104T3
- Authority
- ES
- Spain
- Prior art keywords
- framework regions
- enhanced stability
- identification methods
- intracellular environment
- immunoglobulin framework
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003834 intracellular effect Effects 0.000 title description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 title 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 title 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 108010001515 Galectin 4 Proteins 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38264902P | 2002-05-22 | 2002-05-22 | |
| US382649P | 2002-05-22 | ||
| US43825603P | 2003-01-03 | 2003-01-03 | |
| US438256P | 2003-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2537104T3 true ES2537104T3 (es) | 2015-06-02 |
Family
ID=29553590
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10009857.3T Expired - Lifetime ES2537104T3 (es) | 2002-05-22 | 2003-05-21 | Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelular y métodos de identificación de las mismas |
| ES10010455.3T Expired - Lifetime ES2656427T3 (es) | 2002-05-22 | 2003-05-21 | Marcos de inmunoglobulina que demuestran estabilidad mejorada en el ambiente intracelular y métodos para su identificación |
| ES03732434T Expired - Lifetime ES2399617T3 (es) | 2002-05-22 | 2003-05-21 | Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10010455.3T Expired - Lifetime ES2656427T3 (es) | 2002-05-22 | 2003-05-21 | Marcos de inmunoglobulina que demuestran estabilidad mejorada en el ambiente intracelular y métodos para su identificación |
| ES03732434T Expired - Lifetime ES2399617T3 (es) | 2002-05-22 | 2003-05-21 | Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8853362B2 (cg-RX-API-DMAC7.html) |
| EP (5) | EP1506236B1 (cg-RX-API-DMAC7.html) |
| JP (10) | JP2006508638A (cg-RX-API-DMAC7.html) |
| CN (4) | CN1662556B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2003238370B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2483285C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1114225T1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK1506236T3 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2537104T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE048922T2 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ536412A (cg-RX-API-DMAC7.html) |
| PT (2) | PT2332989E (cg-RX-API-DMAC7.html) |
| SI (2) | SI2947095T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003097697A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0226727D0 (en) * | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| EP2351842A1 (en) | 2005-03-25 | 2011-08-03 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
| PL2390267T3 (pl) | 2005-06-07 | 2013-09-30 | Esbatech A Novartis Co Llc | Stabilne i rozpuszczalne przeciwciała hamujące TNF(alfa) |
| AU2016204739C1 (en) * | 2005-06-07 | 2017-10-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| AU2013207650B2 (en) * | 2005-06-07 | 2016-04-21 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| AU2011265593B2 (en) * | 2005-06-07 | 2013-08-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| CN101443361B (zh) * | 2006-04-28 | 2015-08-19 | 德勒尼克斯治疗股份公司 | 与受体酪氨酸激酶alk的胞外域结合的抗体 |
| CA2658241C (en) | 2006-07-10 | 2018-01-02 | Esbatech Ag | Scfv antibodies which pass epithelial and/or endothelial layers |
| US8280711B2 (en) | 2007-03-12 | 2012-10-02 | ESBATech, an Alcon Biomedical Research Unit, LLC. | Sequence based engineering and optimization of single chain antibodies |
| WO2008131575A2 (en) * | 2007-04-27 | 2008-11-06 | Esbatech Ag | Anti-alk antibodies suitable for treating metastatic cancers or tumors |
| KR101573086B1 (ko) * | 2007-06-25 | 2015-11-30 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 항체를 변형시키는 방법, 및 기능적 특성이 개선된 변형된 항체 |
| NZ581470A (en) | 2007-06-25 | 2013-04-26 | Esbatech Alcon Biomed Res Unit | Sequence based engineering and optimization of single chain antibodies |
| JP5500730B2 (ja) | 2007-09-13 | 2014-05-21 | デレネックス セラピューティクス アーゲー | β−アミロイドペプチドに対するヒト化抗体 |
| LT3216803T (lt) | 2008-06-25 | 2020-06-10 | Novartis Ag | Stabilūs ir tirpūs antikūnai, slopinantys vegf |
| MX2011000052A (es) | 2008-06-25 | 2011-07-29 | Esbatech Alcon Biomed Res Unit | Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal. |
| HUE047678T2 (hu) * | 2008-06-25 | 2020-05-28 | Novartis Ag | Nyúl ellenanyagok humanizálása univerzális ellenanyagváz alkalmazásával |
| AU2015201794B2 (en) * | 2008-06-25 | 2017-01-19 | Novartis Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa |
| AU2016273957C1 (en) * | 2008-06-25 | 2019-04-18 | Novartis Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa |
| AU2009264564B2 (en) | 2008-06-25 | 2014-05-08 | Novartis Ag | Stable and soluble antibodies inhibiting TNFalpha |
| RU2514658C2 (ru) | 2008-06-25 | 2014-04-27 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | Оптимизация растворимости иммуносвязывающих средств |
| AU2013202997B2 (en) * | 2008-06-25 | 2015-01-22 | Novartis Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha |
| SI2752428T1 (sl) * | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| KR101678925B1 (ko) * | 2008-06-30 | 2016-11-24 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 기능화 폴리펩티드 |
| EP2769711A1 (en) | 2008-07-10 | 2014-08-27 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods and Compositions for Enhanced Delivery of Macromolecules |
| MX352922B (es) * | 2009-02-24 | 2017-12-14 | Esbatech Alcon Biomed Res Unit | Métodos para identificar inmunoligadores de los antígenos de la superficie celular. |
| AU2010217120B2 (en) | 2009-02-24 | 2014-11-20 | Novartis Ag | Methods for identifying immunobinders of cell-surface antigens |
| US8399625B1 (en) | 2009-06-25 | 2013-03-19 | ESBATech, an Alcon Biomedical Research Unit, LLC | Acceptor framework for CDR grafting |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| EP2476754A1 (en) * | 2011-01-14 | 2012-07-18 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
| EP2744931B1 (en) | 2011-08-18 | 2018-05-02 | Affinity Biosciences Pty Ltd | Soluble polypeptides |
| CN109608543A (zh) | 2011-10-20 | 2019-04-12 | 艾斯巴技术-诺华有限责任公司 | 稳定的多抗原结合抗体 |
| CN113234142B (zh) * | 2012-08-22 | 2024-03-05 | 财团法人牧岩生命工学研究所 | 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 |
| EP3750917A1 (en) | 2012-11-05 | 2020-12-16 | Delenex Therapeutics AG | Binding members to il-1 beta |
| ES2895848T3 (es) | 2012-12-17 | 2022-02-22 | Cell Medica Inc | Anticuerpos contra IL-1 beta |
| EP2956478A1 (en) * | 2013-02-15 | 2015-12-23 | ESBATech - a Novartis Company LLC | Acceptor framework for cdr grafting |
| RU2015139890A (ru) * | 2013-02-20 | 2017-03-27 | ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи | Акцепторный каркасный участок для пересадки cdr |
| SG10201800800YA (en) | 2013-05-06 | 2018-03-28 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
| US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
| CA2967595A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX2018004515A (es) * | 2015-10-13 | 2019-04-15 | Eureka Therapeutics Inc | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. |
| CN107614519B (zh) | 2015-10-23 | 2022-08-05 | 优瑞科生物技术公司 | 抗体/t细胞受体嵌合构建体及其用途 |
| CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| EP3420000A1 (en) | 2016-02-25 | 2019-01-02 | Cell Medica Switzerland AG | Modified cells for immunotherapy |
| MX2019003225A (es) * | 2016-09-21 | 2019-06-10 | Aptevo Res & Development Llc | Proteínas de unión a cd123 y composiciones y métodos relacionados. |
| EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| JP2020510671A (ja) | 2017-03-03 | 2020-04-09 | シアトル ジェネティックス， インコーポレイテッド | グリカン相互作用化合物および使用の方法 |
| JP7416433B2 (ja) * | 2018-04-10 | 2024-01-17 | ノースウェスタン ユニバーシティ | 標的指向性親和性ドメインに基づく膜タンパク質を含む細胞外小胞 |
| US20200102373A1 (en) * | 2018-09-27 | 2020-04-02 | Colorado State University Research Foundation | Scfv's for live cell imaging and other uses |
| US12285437B2 (en) | 2019-10-30 | 2025-04-29 | The Research Foundation For The State University Of New York | Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity |
| MX2023000547A (es) | 2020-07-16 | 2023-02-13 | Novartis Ag | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas. |
| US20240150449A1 (en) | 2021-03-10 | 2024-05-09 | Mabylon Ag | Antibodies against tdp-43 and methods of using the same |
| US20250101089A1 (en) | 2022-01-24 | 2025-03-27 | Cambridge Enterprise Limited | Tau therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
| DE4425115A1 (de) | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
| DK1143006T3 (da) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| US7264963B1 (en) * | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| US6262238B1 (en) | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
| EP1040201A4 (en) | 1997-11-28 | 2001-11-21 | Invitrogen Corp | SINGLE CHAIN MONOCLONAL ANTIBODY FUSION AGENTS THAT REGULATE IN VIVO TRANSCRIPTION |
| GB2344886B (en) | 1999-03-10 | 2000-11-01 | Medical Res Council | Selection of intracellular immunoglobulins |
| DK1242457T3 (da) | 1999-12-28 | 2004-12-20 | Esbatech Ag | Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| EP1156062A1 (en) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| US6410271B1 (en) | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Generation of highly diverse library of expression vectors via homologous recombination in yeast |
| DE10039191C1 (de) | 2000-08-10 | 2002-01-17 | Infineon Technologies Ag | Hochfrequenz-Eingangsstufe |
-
2003
- 2003-05-21 US US10/515,241 patent/US8853362B2/en not_active Expired - Lifetime
- 2003-05-21 ES ES10009857.3T patent/ES2537104T3/es not_active Expired - Lifetime
- 2003-05-21 DK DK03732434.0T patent/DK1506236T3/da active
- 2003-05-21 PT PT100098573T patent/PT2332989E/pt unknown
- 2003-05-21 PT PT37324340T patent/PT1506236E/pt unknown
- 2003-05-21 ES ES10010455.3T patent/ES2656427T3/es not_active Expired - Lifetime
- 2003-05-21 EP EP03732434A patent/EP1506236B1/en not_active Expired - Lifetime
- 2003-05-21 HU HUE15160739A patent/HUE048922T2/hu unknown
- 2003-05-21 EP EP10009857.3A patent/EP2332989B1/en not_active Expired - Lifetime
- 2003-05-21 CN CN038146266A patent/CN1662556B/zh not_active Expired - Lifetime
- 2003-05-21 WO PCT/EP2003/005324 patent/WO2003097697A2/en not_active Ceased
- 2003-05-21 JP JP2004506369A patent/JP2006508638A/ja not_active Withdrawn
- 2003-05-21 EP EP10010455.3A patent/EP2314622B1/en not_active Expired - Lifetime
- 2003-05-21 CA CA2483285A patent/CA2483285C/en not_active Expired - Lifetime
- 2003-05-21 CN CN201410031953.4A patent/CN103739706B/zh not_active Expired - Lifetime
- 2003-05-21 SI SI200332610T patent/SI2947095T1/sl unknown
- 2003-05-21 AU AU2003238370A patent/AU2003238370B2/en not_active Expired
- 2003-05-21 ES ES03732434T patent/ES2399617T3/es not_active Expired - Lifetime
- 2003-05-21 NZ NZ536412A patent/NZ536412A/en not_active IP Right Cessation
- 2003-05-21 EP EP15160739.7A patent/EP2947095B1/en not_active Expired - Lifetime
- 2003-05-21 DK DK10009857.3T patent/DK2332989T3/en active
- 2003-05-21 EP EP19200477.8A patent/EP3656787A1/en not_active Withdrawn
- 2003-05-21 CA CA2867542A patent/CA2867542C/en not_active Expired - Lifetime
- 2003-05-21 CN CN201510685456.0A patent/CN105175535A/zh active Pending
- 2003-05-21 CN CN201010575786.1A patent/CN102093477B/zh not_active Expired - Lifetime
- 2003-05-21 SI SI200332427T patent/SI2332989T1/sl unknown
-
2010
- 2010-03-17 JP JP2010060713A patent/JP2010187678A/ja not_active Withdrawn
- 2010-06-24 AU AU2010202634A patent/AU2010202634B2/en not_active Expired
-
2012
- 2012-08-28 JP JP2012187518A patent/JP6075836B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-04 JP JP2013019425A patent/JP6100544B2/ja not_active Expired - Lifetime
- 2013-04-08 CY CY20131100292T patent/CY1114225T1/el unknown
- 2013-09-19 JP JP2013193935A patent/JP2013256533A/ja active Pending
-
2014
- 2014-08-26 US US14/469,276 patent/US9518108B2/en not_active Expired - Fee Related
-
2015
- 2015-08-19 JP JP2015161600A patent/JP6261136B2/ja not_active Expired - Lifetime
- 2015-08-19 JP JP2015161601A patent/JP2015214583A/ja active Pending
-
2016
- 2016-11-01 US US15/340,195 patent/US10125186B2/en not_active Expired - Lifetime
-
2017
- 2017-08-24 JP JP2017161036A patent/JP2017201990A/ja active Pending
-
2018
- 2018-10-30 US US16/175,002 patent/US10570190B2/en not_active Expired - Fee Related
-
2019
- 2019-01-23 JP JP2019009288A patent/JP6918033B2/ja not_active Expired - Lifetime
- 2019-12-16 US US16/716,137 patent/US20200165322A1/en not_active Abandoned
-
2020
- 2020-05-14 JP JP2020085288A patent/JP2020171286A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2537104T3 (es) | Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelular y métodos de identificación de las mismas | |
| Liu et al. | Establishment and evolution of heterochromatin | |
| Yuwen et al. | Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene | |
| Vermaak et al. | Centromere targeting element within the histone fold domain of Cid | |
| Dai et al. | Actin microfilament mediates osteoblast Cbfa1 responsiveness to BMP2 under simulated microgravity | |
| Guo et al. | The NS16 protein of aquareovirus-C is a fusion-associated small transmembrane (FAST) protein, and its activity can be enhanced by the nonstructural protein NS26 | |
| Seiradake et al. | Production of cell surface and secreted glycoproteins in mammalian cells | |
| AR020331A1 (es) | Construccion, y metodo para producir una proteina en una celula de planta | |
| ES2547700T3 (es) | Nueva línea de células humanas permanente | |
| Doyle et al. | Two domains that control prefusion stability and transport competence of the measles virus fusion protein | |
| Fonstein et al. | Chromosomal structure of Rhodobacter capsulatus strain SB1003: cosmid encyclopedia and high-resolution physical and genetic map. | |
| BR9911270A (pt) | Métodos e meios para expressão de polipeptìdeos de mamìferos em plantas monocotiledÈneas | |
| HRP20192243T1 (hr) | Polipeptidni ekspresijski sustavi | |
| CN114958912A (zh) | 一种hek293细胞瞬时表达转染用试剂和瞬时表达系统转染方法 | |
| Zhang et al. | Multiple tandem epitope tagging for enhanced detection of protein expressed in mammalian cells | |
| De Loof | Problems and paradigms. All animals develop from a blastula: Consequences of an undervalued definition for thinking on development | |
| CN108795982A (zh) | 一种鸡干扰素α生物学活性检测方法 | |
| De la Concepcion et al. | Electrostatic changes enabled the diversification of an exocyst subunit via protein complex escape | |
| Makuch | Yeast two-hybrid screen | |
| Bétermier et al. | Functional domains of bacteriophage Mu transposase: properties of C‐terminal deletions | |
| ES2507665T3 (es) | Recombinación de ADN específica de secuencia en células eucariotas | |
| Clayton | The cytoskeleton and the plant cell cycle | |
| Xu et al. | A mammalian expression system for high throughput antibody screening | |
| Shimpi et al. | Ancient endosymbiont‐mediated transmission of a selfish gene provides a model for overcoming barriers to gene transfer into animal mitochondrial genomes | |
| Mizutani et al. | Modified S/MAR episomal vectors for stably expressing fluorescent protein-tagged transgenes with small cell-to-cell fluctuations |